Samsung Epys Holdings Officially Launched as Bio-Investment Holding Company

Official Launch on November 1 Following Spin-Off

Samsung Epys Holdings, the newly established entity resulting from the spin-off of Samsung Biologics and serving as a bio-investment holding company, was officially launched on November 1, marking the beginning of its full-scale operations.

According to industry sources on November 3, Samsung Epys Holdings will have Samsung Bioepis, a biopharmaceutical development and commercialization company focused on the biosimilar business, as its wholly owned subsidiary. The company will also establish a new subsidiary dedicated to the development of bio-technology platforms. Samsung Epys Holdings plans to maximize both corporate and shareholder value by establishing optimal business strategies for each subsidiary and pursuing active research and development as well as investments.

First, the company aims to further strengthen its biosimilar business capabilities, which have been highly developed over the past 13 years. Since its establishment in 2012, Samsung Bioepis has successfully developed and launched biosimilars for 11 blockbuster biopharmaceuticals. Last year, the company recorded its highest-ever performance with sales of 1.5377 trillion won and operating profit of 435.4 billion won.

Samsung Bioepis plans to focus on research and development to secure more than 20 competitive products and pipelines in the biosimilar industry, which is expected to continue its growth in line with global trends such as population aging and an increase in patients with chronic diseases.

Additionally, Samsung Epys Holdings plans to actively explore promising new businesses based on next-generation technologies for future growth by establishing a new subsidiary. This subsidiary will focus on developing next-generation bio-technology platforms targeting various modalities (therapeutic approaches), aiming to discover new growth engines and drive innovation beyond the biosimilar business.

The new subsidiary is expected to adopt a biotech model as its core business, platformizing highly scalable core technologies and developing a variety of new drug candidates, including joint development with global pharmaceutical companies.

Kyeongah Kim has been appointed as the inaugural CEO of Samsung Epys Holdings. Kim will also continue to serve as CEO of Samsung Bioepis, overseeing the management of both the holding company and its business subsidiaries.

Kyeongah Kim, the inaugural president of Samsung Biologics Holdings. Samsung Biologics

Kyeongah Kim stated, "The launch of Samsung Epys Holdings will serve as a turning point for a new leap forward to lead the future global bio industry. Moving forward, we will enhance synergies across all business sectors and create a unique success story for Epys to contribute to a better life for humanity."

Samsung Epys Holdings plans to complete the necessary legal procedures as a newly established corporation, establish its new subsidiary by November 14, and be relisted on the Korea Exchange on November 24.

Meanwhile, Samsung Epys Holdings launched its official website upon its establishment, providing information on its business, sustainability management, and investment details. The company plans to utilize the website as a transparent communication channel for global stakeholders.

This content was produced with the assistance of AI translation services.